PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31360064-0 2019 Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed. Pemetrexed 97-107 ret proto-oncogene Homo sapiens 74-77 31360064-3 2019 We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions. Pemetrexed 105-115 ret proto-oncogene Homo sapiens 54-57 31360064-3 2019 We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions. Pemetrexed 105-115 ret proto-oncogene Homo sapiens 253-256 31360064-3 2019 We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions. Pemetrexed 204-214 ret proto-oncogene Homo sapiens 54-57 31360064-3 2019 We here report a case of NSCLC positive for the CCDC6-RET fusion gene that benefited from treatment with pemetrexed over a period of 30 months, suggesting that thymidylate synthase-targeted drugs such as pemetrexed may show efficacy for NSCLC harboring RET fusions. Pemetrexed 204-214 ret proto-oncogene Homo sapiens 253-256